Ombitasvir
TECHNIVIE
What it isHCV NS5A inhibitor; hepatitis C in older combination regimens.
Why this oneIt contributed to the first interferon-free cures in genotype 1.
What limits itSuperseded by pangenotypic regimens. Hepatitis B reactivation; ritonavir-driven interactions.
FDA-approved for
- chronic hepatitis C (2014)
NO BOXED WARNINGS
Principal riskSuperseded by pangenotypic regimens
Classes and tags
Clinical profile
Mechanism of action: Ombitasvir ballicule
